Other Events ·
Evommune, Inc. announced on June 29, 2026, that its Phase 2b trial for EVO756 in treating moderate-to-severe chronic…
EVMNEvommune, Inc.
Evommune, Inc. announced on June 29, 2026, that its Phase 2b trial for EVO756 in treating moderate-to-severe chronic spontaneous urticaria (CSU) failed to meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks across all dose regimens. Consequently, the Company plans to cease development of EVO756 for the CSU indication. Evommune, Inc. is a biotechnology company focused on developing immune-mediated disease treatments.